Experienced in Essential Thrombocythemia

Dr. Bruno S. Fang

Titan Health Partners LLC
East Brunswick, NJ
Experienced
in Essential Thrombocythemia
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Bruno Fang is a Hematologist Oncology specialist and an Oncologist in East Brunswick, New Jersey. Dr. Fang and is rated as an Experienced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Lung Cancer, Hodgkin Lymphoma, Pleuropulmonary Blastoma, and Familial Colorectal Cancer. Dr. Fang is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NJ
Hospital Affiliations
Robert Wood Johnson University Hospital At Hamilton
University Medical Center Of Princeton At Plainsboro
Saint Peter's University Hospital
Robert Wood Johnson University Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

TITAN HEALTH PARTNERS LLC
J2 Brier Hill Ct, East Brunswick, NJ 08816
732-390-7750

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug
Study Phase: Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Study Phase: Phase 1
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drugs: Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab govitecan
Study Phase: Phase 2
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Metformin, Dapagliflozin
Study Phase: Phase 2
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 30, 2024
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2024
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2023
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Enrollment Status: Terminated
Publish Date: July 20, 2018
Intervention Type: Diagnostic test
View 11 Less Clinical Trials

9 Total Publications

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Journal: Radiology
Published: August 20, 2024
Similar Doctors
Expertise in
36
conditions
Dr. John O. Mascarenhas
Hematology Oncology | Hematology
Expertise in
36
conditions
Dr. John O. Mascarenhas
Hematology Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (36.1 mi)
212-731-7650
Languages Spoken:
English
See accepted insurances

John Mascarenhas is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Mascarenhas and is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Splenectomy.

Expertise in
39
conditions
Dr. Raajit K. Rampal
Oncology | Hematology
Expertise in
39
conditions
Dr. Raajit K. Rampal
Oncology | Hematology

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (34.6 mi)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Raajit Rampal is an Oncologist and a Hematologist in New York, New York. Dr. Rampal and is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Myeloproliferative Neoplasms (MPN), Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
27
conditions
Dr. Marina Kremyanskaya
Oncology | Hematology
Expertise in
27
conditions
Dr. Marina Kremyanskaya
Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (35.9 mi)
212-241-4812
Languages Spoken:
English
See accepted insurances

Marina Kremyanskaya is an Oncologist and a Hematologist in New York, New York. Dr. Kremyanskaya and is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile